Radionuclide approach to tumor detection

Abstract

A considerable amount of the nuclear medicine physician's attention is directed toward the screening of patients for tumor diagnosis or for the growth or metastasis of known tumor. Two basic techniques of radionuclide tumor detection are (I) rendering the normal tissue in an organ radioactive and looking for abnormal, nonradioactive areas which represent tumor involvement and (2) making the tumor itself radioactive and hence readily detectable in the relatively nonradioactive normal tissue. Liver, kidney, and thyroid scanning utilize the first method, while metastatic thyroid, brain, and bone tumor scans are examples of the second. The superiority of the technique for finding a hot or bright lesion in a cold or dark background has prompted attempts at extension of this method to the search for tumors. Among the newer agents which specifically label tumors and are being evaluated are Ga6'-citrate in lung carcinomas and lymphomas, Se75-selenite in brain and bone tumors, radioiodinated antifibrinogen for various tumors, and radioiodinated iodoquine in malignant melanoma.

A STUDY ON THE CALCULATIONS OF CROSS–SECTIONS FOR 66,67Ga AND 75Se RADIONUCLIDES PRODUCTION REACTIONS VIA 3He PARTICLES

“…67 Ga, which has 78 hours of half-life and mostly produced via cyclotrons, used for tumour imaging and locating inflammatory lesions also for osteomyelitis detection, evaluation of sarcoidosis and other granulomatous diseases particularly in lungs and mediastinum by employing either a gamma camera or a Single Photon Emission Computerized Tomography (SPECT) camera. In addition, it is possible to use a hybrid machine known as SPECT/CT (computerized tomography) [2,3]. On the other hand, 75 Se has been using as radiotracer in brain studies and scintigraphy scanning.…”

“…On the other hand, 75 Se has been using as radiotracer in brain studies and scintigraphy scanning. Also, for some situations it may preferred due to its long half-life advantage, which is 120 days [2,4].…”